Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Las Vegas Sands Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Las Vegas Sands Corp. trades at $46.6 (market cap $30.94B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.36% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LVS | |
|---|---|---|
Market Cap | $39.89B | $30.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $69.49 |
52-Week Low | $278.09 | $46.06 |
Enterprise Value | $38.15B | $43.33B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LVS trades at $46.69, up 0.52% with a bearish technical signal despite strong fundamentals. The company demonstrates robust revenue growth, reaching $13.02B in 2025 with consistent earnings beats and a 13.41% net margin. Analyst consensus remains strongly bullish with a $66.89 price target, though technical indicators show selling pressure with support at $46.
LVS presents a compelling investment case with strong operational performance and analyst support, though technical weakness and high debt levels pose risks. The stock offers significant upside potential from current levels if fundamental strength continues, but investors should monitor debt management and Macau market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
